Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

Vaccine

Volumn 28, Issue 4, 2010, Pages 965-969

  Leav, Brett A ^a   Blair, Barbra ^a   Leney, Mark ^a   Knauber, Michael ^a   Reilly, Courtney ^a   Lowy, Israel ^b   Gerding, Dale N ^c   Kelly, Ciarán P ^d   Katchar, Kia ^d   Baxter, Roger ^e   Ambrosino, Donna ^a   Molrine, Deborah ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MEDAREX INC   (United States)

^c Research   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

Clostridium difficile; Monoclonal antibody; Toxin

Indexed keywords

CDA1 MONOCLONAL ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MORTALITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SINGLE DRUG DOSE;

AGED; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FEMALE; HUMANS; MALE; PLACEBOS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 74249096590     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.144     Document Type: Article

References (29)

1. McDonald L.C., Owings M., and Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12 March (3) (2006) 409-415
2. Redelings M.D., Sorvillo F., and Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 13 September (9) (2007) 1417-1419
3. Curry S.R., Marsh J.W., Muto C.A., O'Leary M.M., Pasculle A.W., and Harrison L.H. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45 January (1) (2007) 215-221
4. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 December (23) (2005) 2442-2449
5. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 December (23) (2005) 2433-2441
6. McEllistrem M.C., Carman R.J., Gerding D.N., Genheimer C.W., and Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 40 January (2) (2005) 265-272
7. Hubert B., Loo V.G., Bourgault A.M., Poirier L., Dascal A., Fortin E., et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 44 January (2) (2007) 238-244
8. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 September (9491) (2005) 1079-1084
9. Bacon III A.E., and Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis 18 April (4) (1994) 205-209
10. Viscidi R., Laughon B.E., Yolken R., Bo-Linn P., Moench T., Ryder R.W., et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 148 July (1) (1983) 93-100
11. Kyne L., Warny M., Qamar A., and Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 February (6) (2000) 390-397
12. Kyne L., Warny M., Qamar A., and Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357 January (9251) (2001) 189-193
13. McPherson S., Rees C.J., Ellis R., Soo S., and Panter S.J. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 49 May (5) (2006) 640-645
14. Salcedo J., Keates S., Pothoulakis C., Warny M., Castagliuolo I., LaMont J.T., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41 September (3) (1997) 366-370
15. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53 May (5) (2004) 882-884
16. Babcock G.J., Broering T.J., Hernandez H.J., Mandell R.B., Donahue K., Boatright N., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74 November (11) (2006) 6339-6347
17. Taylor C.P., Tummala S., Molrine D., Davidson L., Farrell R.J., Lembo A., et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 26 June (27-28) (2008) 3404-3409
18. Womble H., Davidson L., Swan S., Lowy I., Hibberd P., and Molrine D. Safety and pharmacokinetics of human monoclonal antibodies to Clostridium difficile toxin A and toxin B in healthy adults (2007), Infectious Diseases Society of America, San Diego
19. Kyne L., Sougioultzis S., McFarland L.V., and Kelly C.P. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 23 November (11) (2002) 653-659
20. Warny M., Vaerman J.P., Avesani V., and Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 62 February (2) (1994) 384-389
21. Clabots C.R., Johnson S., Bettin K.M., Mathie P.A., Mulligan M.E., Schaberg D.R., et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 31 July (7) (1993) 1870-1875
22. Killgore G., Thompson A., Johnson S., Brazier J., Kuijper E., Pepin J., et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 46 February (2) (2008) 431-437
23. Aronsson B., Granstrom M., Mollby R., and Nord C.E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13 May-June (3) (1985) 97-101
24. Giannasca P.J., Zhang Z.X., Lei W.D., Boden J.A., Giel M.A., Monath T.P., et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 67 February (2) (1999) 527-538
25. Kim P.H., Iaconis J.P., and Rolfe R.D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 55 December (12) (1987) 2984-2992
26. Kink J.A., and Williams J.A. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66 May (5) (1998) 2018-2025
27. Pepin J., Valiquette L., and Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173 October (9) (2005) 1037-1042
28. Pepin J., Valiquette L., Gagnon S., Routhier S., and Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102 December (12) (2007) 2781-2788
29. Lyras D., O'Connor J.R., Howarth P.M., Sambol S.P., Carter G.P., Phumoonna T., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458 April (7242) (2009) 1176-1179